Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 7;15:4825–4845. doi: 10.2147/IJN.S251277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Tumor penetration behavior of β-Lapachone/BDOX-CCS. (A) tumor sections were collected, and DOX fluorescence was assessed via CLSM, 24h and 48 h post-treatment. (B and C) UV-Vis spectrometry was used to quantify DOX levels in (B) central tumor interstitial regions (100 mm³) and (C) throughout the HepG2 tumors after one intravenous injection of β-Lapachone/BDOX-NCS, β-Lapachone/BDOX-CCS, and US + β-Lapachone/BDOX-CCS. (D) Penetration indexes (P-index) of β-Lapachone/BDOX-CCS were obtained by dividing central interstitial DOX levels by the total tumor DOX levels. All results were calculated based on three independent experiments (**p<0.01).